ArticleCardiovascular and interventional radiology2026
Comparison of the 8F Zelante and 6F Solent Angiojet Thrombectomy Catheter in the Treatment of Acute Pulmonary Embolism.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo compare the efficacy of the 8F Zelante and 6F Solent Angiojet thrombectomy catheters in the treatment of acute pulmonary embolism (PE).
methodsA retrospective multicenter study was conducted, collecting data from patients with acute PE between January 2019 and December 2024. A total of 98 cases were included based on inclusion and exclusion criteria. Patients were divided into two groups based on the Angiojet catheter used: the 8F group and the 6F group, and then matched at a 1:1 ratio. The primary outcomes comprised 7-day all-cause mortality, the need for bailout thrombolysis, and perioperative changes in ancillary and laboratory parameters. The secondary outcome comprised treatment-related complications, including arrhythmias, hypotension, hemoptysis, aggravation of chest tightness, severe acute renal insufficiency, and hemoglobinuria.
resultsTwenty-seven patients were included in each group. The 7-day all-cause mortality did not differ significantly between the 8F and 6F group [(2/27) vs. (3/27), P = 1.000]. The need for bailout thrombolysis was significantly higher in the 6F group [(17/27) vs. (8/27), P = 0.028]. A statistically significant intergroup difference was found in the reduction of Miller index and mean pulmonary artery pressure (MPAP) during the perioperative period. The incidence of transient arrhythmias was significantly higher in the 8F group [(21/27) vs. (11/27), P = 0.012]. The incidence of other complications did not differ between groups.
conclusionCompared to the 6F Solent catheter, the 8F Zelante catheter demonstrated superior thrombectomy efficacy in PE, reducing the need for bailout thrombolysis-a potential benefit for patients with contraindications to thrombolysis. This advantage, however, was accompanied by a higher incidence of transient arrhythmias.
Indexed as
Identifiers
41786963What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.